Related Experiment Video
Updated: May 11, 2026
A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
Published on: September 26, 2011
Gliadel for brain metastasis
Taylor J Abel1, Timothy Ryken, Maciej S Lesniak
1Department of Neurosurgery, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Abstract:
With therapies for systemic malignancy improving, life expectancy for cancer patients is becoming increasingly dependent on control of brain metastatic disease. Despite improvements in surgical and radiotherapy modalities for control of brain metastasis, the prognosis for patients with brain metastases is poor. The development of controlled release polymers has lead to novel new therapies for malignant brain tumors consisting of direct surgical delivery of chemotherapy agents to the tumor bed and sustained chemotherapy release over a prolonged period of time. Although there is a large body of literature in support of BCNU polymer wafer for primary brain malignancy and experimental brain metastases, clinical studies evaluating the BCNU polymer wafer for brain metastatic disease are relatively sparse. In this review, we discuss the role of the BCNU polymer wafer for brain metastasis focusing specifically on rationale for use of locally delivered sustained release polymers, history of the BCNU polymer wafer, and emerging studies examining the role of the BCNU polymer wafer for metastatic brain tumors.
Insights
The BCNU polymer wafer offers localized, sustained chemotherapy delivery for brain metastases. This review explores its use in managing metastatic brain tumors, a critical factor in improving cancer patient survival.
Area of Science:
- Neuro-oncology
- Polymer science
- Drug delivery systems
Background:
- Improving systemic cancer therapies increase reliance on controlling brain metastases for patient survival.
- Despite advances in surgery and radiotherapy, brain metastases still carry a poor prognosis.
- Controlled-release polymers enable direct surgical delivery of chemotherapy to the tumor bed.
Purpose of the Study:
- To review the role of the BCNU polymer wafer in treating brain metastases.
- To discuss the rationale for using locally delivered, sustained-release polymers.
- To examine emerging clinical studies on the BCNU polymer wafer for metastatic brain tumors.
Main Methods:
- Literature review focusing on BCNU polymer wafer applications in brain metastases.
- Analysis of studies on direct surgical delivery and sustained chemotherapy release.
- Examination of clinical data for metastatic brain tumors.
Main Results:
- While extensively studied for primary brain tumors, clinical data on BCNU polymer wafers for brain metastases are limited.
- The BCNU polymer wafer facilitates localized and sustained release of chemotherapy directly to the tumor site.
- Emerging studies suggest potential efficacy in managing metastatic brain disease.
Conclusions:
- The BCNU polymer wafer represents a promising localized therapy for brain metastases.
- Further clinical investigation is warranted to establish its efficacy and role in improving outcomes for patients with metastatic brain tumors.
- Controlled-release polymer technology offers a novel approach to brain tumor treatment.
